These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33249369)

  • 1. Microarray-based analysis of the BRAF V600 mutations in circulating tumor DNA in melanoma patients.
    Emelyanova MA; Telysheva EN; Orlova KV; Ryabaya OO; Snigiryova GP; Abramov IS; Mikhailovich VM
    Cancer Genet; 2021 Jan; 250-251():25-35. PubMed ID: 33249369
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct comparison study between droplet digital PCR and a combination of allele-specific PCR, asymmetric rapid PCR and melting curve analysis for the detection of BRAF V600E mutation in plasma from melanoma patients.
    Tzanikou E; Haselmann V; Markou A; Duda A; Utikal J; Neumaier M; Lianidou ES
    Clin Chem Lab Med; 2020 Oct; 58(11):1799-1807. PubMed ID: 31953992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative analysis of the BRAF
    Ashida A; Sakaizawa K; Mikoshiba A; Uhara H; Okuyama R
    Int J Clin Oncol; 2016 Oct; 21(5):981-988. PubMed ID: 27041702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
    Seremet T; Planken S; Schreuer M; Jansen Y; Delaunoy M; El Housni H; Lienard D; Del Marmol V; Heimann P; Neyns B
    Melanoma Res; 2018 Feb; 28(1):65-70. PubMed ID: 29227333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal Relationship between Idylla Plasma ctBRAF V600 Mutation Detection and Tumor Burden in Patients with Metastatic Melanoma.
    Linder MW; Egger ME; Van Meter T; Rai SN; Valdes R; Hall MB; Wu X; Alghamdi N; Chesney JA
    Mol Diagn Ther; 2021 May; 25(3):361-371. PubMed ID: 33970440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liquid biopsy-based analysis by ddPCR and CAPP-Seq in melanoma patients.
    Kaneko A; Kanemaru H; Kajihara I; Mijiddorj T; Miyauchi H; Kuriyama H; Kimura T; Sawamura S; Makino K; Miyashita A; Aoi J; Makino T; Masuguchi S; Fukushima S; Ihn H
    J Dermatol Sci; 2021 Jun; 102(3):158-166. PubMed ID: 34049769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma.
    Gouda MA; Polivka J; Huang HJ; Treskova I; Pivovarcikova K; Fikrle T; Woznica V; Dustin DJ; Call SG; Meric-Bernstam F; Pesta M; Janku F
    ESMO Open; 2022 Feb; 7(1):100357. PubMed ID: 34942440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA (ctDNA) detection is associated with shorter progression-free survival in advanced melanoma patients.
    Marczynski GT; Laus AC; Dos Reis MB; Reis RM; Vazquez VL
    Sci Rep; 2020 Oct; 10(1):18682. PubMed ID: 33122747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. USE OF CIRCULATING TUMOR DNA FOR DETECTION OF BRAF V600E MUTATION AND TREATMENT MONITORING IN MELANOMA PATIENTS.
    Shapochka D; Shapochka T; Seleznyov O; Matveeva A; Dudin V
    Georgian Med News; 2018 Mar; (276):76-81. PubMed ID: 29697386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interlaboratory assessment of droplet digital PCR for quantification of BRAF V600E mutation using a novel DNA reference material.
    Dong L; Wang X; Wang S; Du M; Niu C; Yang J; Li L; Zhang G; Fu B; Gao Y; Wang J
    Talanta; 2020 Jan; 207():120293. PubMed ID: 31594564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clonal dynamics of circulating tumor DNA during immune checkpoint blockade therapy for melanoma.
    Takai E; Omata W; Totoki Y; Nakamura H; Shiba S; Takahashi A; Namikawa K; Mori T; Yamazaki N; Shibata T; Yachida S
    Cancer Sci; 2021 Nov; 112(11):4748-4757. PubMed ID: 34477284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of BRAF mutation status in circulating tumor DNA of metastatic melanoma patients at baseline.
    Knol AC; Vallée A; Herbreteau G; Nguyen JM; Varey E; Gaultier A; Théoleyre S; Saint-Jean M; Peuvrel L; Brocard A; Quéreux G; Khammari A; Denis MG; Dréno B
    Exp Dermatol; 2016 Oct; 25(10):783-8. PubMed ID: 27194447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma.
    Garlan F; Blanchet B; Kramkimel N; Puszkiel A; Golmard JL; Noe G; Dupin N; Laurent-Puig P; Vidal M; Taly V; Thomas-Schoemann A
    Target Oncol; 2017 Jun; 12(3):365-371. PubMed ID: 28527094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liquid Profiling of Circulating Tumor DNA in Plasma of Melanoma Patients for Companion Diagnostics and Monitoring of BRAF Inhibitor Therapy.
    Haselmann V; Gebhardt C; Brechtel I; Duda A; Czerwinski C; Sucker A; Holland-Letz T; Utikal J; Schadendorf D; Neumaier M
    Clin Chem; 2018 May; 64(5):830-842. PubMed ID: 29483107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamic ctDNA Mutational Complexity in Patients with Melanoma Receiving Immunotherapy.
    Fitzgerald S; Blenkiron C; Stephens R; Mathy JA; Somers-Edgar T; Rolfe G; Martin R; Jackson C; Eccles M; Robb T; Rodger E; Lawrence B; Guilford P; Lasham A; Print CG
    Mol Diagn Ther; 2023 Jul; 27(4):537-550. PubMed ID: 37099071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations.
    Tsao SC; Weiss J; Hudson C; Christophi C; Cebon J; Behren A; Dobrovic A
    Sci Rep; 2015 Jun; 5():11198. PubMed ID: 26095797
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma.
    Lee RJ; Gremel G; Marshall A; Myers KA; Fisher N; Dunn JA; Dhomen N; Corrie PG; Middleton MR; Lorigan P; Marais R
    Ann Oncol; 2018 Feb; 29(2):490-496. PubMed ID: 29112704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of BRAF-V600E and V600K in melanoma circulating tumour cells by droplet digital PCR.
    Reid AL; Freeman JB; Millward M; Ziman M; Gray ES
    Clin Biochem; 2015 Oct; 48(15):999-1002. PubMed ID: 25523300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.
    Yao J; Zang W; Ge Y; Weygant N; Yu P; Li L; Rao G; Jiang Z; Yan R; He L; Yu Y; Jin M; Cheng G; An G
    Can J Gastroenterol Hepatol; 2018; 2018():4248971. PubMed ID: 29707525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.